Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.7K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

3.6K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.

The Lancet. Respiratory medicine·2026
Same author

Attitudes and Practices Regarding Dosing Interval Extension of Biologics in Severe Asthma: A Nationwide Survey and Real-World Data From the Dutch RAPSODI Registry.

The journal of allergy and clinical immunology. In practice·2026
Same author

Multimorbidity phenotypes and associated characteristics in severe asthma: an observational study of European severe asthma registries.

The Lancet regional health. Europe·2026
Same author

Impact of Sex on Prediction of Asthma Attacks by Clinical Risk Factors and Type 2 Biomarkers.

Chest·2026
Same author

Extracellular Matrix and Endothelial Activation Markers in the Bronchial and Pulmonary Arteries in COPD.

The clinical respiratory journal·2025
Same author

Impact of Dupilumab for Severe Asthma on Fatigue, Quality of Life, Work Productivity, and Activity.

The journal of allergy and clinical immunology. In practice·2025

Related Experiment Video

Updated: Mar 20, 2026

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

8.2K

Lung function decline in asthma patients with elevated bronchial CD8, CD4 and CD3 cells.

Irene den Otter1, Luuk N A Willems2, Annemarie van Schadewijk2

  • 1Dept of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands I.den_Otter@lumc.nl.

The European Respiratory Journal
|May 28, 2016
PubMed
Summary

Asthma patients with higher baseline CD8 and CD4 immune cell counts in their airways show faster lung function decline over 14 years. Elevated CD8, CD3, and granzyme B levels at follow-up also predict lung function loss in asthma.

More Related Videos

Human Lung Dendritic Cells: Spatial Distribution and Phenotypic Identification in Endobronchial Biopsies Using Immunohistochemistry and Flow Cytometry
11:02

Human Lung Dendritic Cells: Spatial Distribution and Phenotypic Identification in Endobronchial Biopsies Using Immunohistochemistry and Flow Cytometry

Published on: January 20, 2017

9.7K
Analysis of Pulmonary Dendritic Cell Maturation and Migration during Allergic Airway Inflammation
07:52

Analysis of Pulmonary Dendritic Cell Maturation and Migration during Allergic Airway Inflammation

Published on: July 23, 2012

15.5K

Related Experiment Videos

Last Updated: Mar 20, 2026

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

8.2K
Human Lung Dendritic Cells: Spatial Distribution and Phenotypic Identification in Endobronchial Biopsies Using Immunohistochemistry and Flow Cytometry
11:02

Human Lung Dendritic Cells: Spatial Distribution and Phenotypic Identification in Endobronchial Biopsies Using Immunohistochemistry and Flow Cytometry

Published on: January 20, 2017

9.7K
Analysis of Pulmonary Dendritic Cell Maturation and Migration during Allergic Airway Inflammation
07:52

Analysis of Pulmonary Dendritic Cell Maturation and Migration during Allergic Airway Inflammation

Published on: July 23, 2012

15.5K

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Respiratory Research

Background:

  • Asthma is a chronic respiratory disease characterized by airway inflammation.
  • Long-term lung function decline in asthma patients is a significant clinical concern.
  • Identifying biomarkers for predicting disease progression is crucial for personalized treatment.

Purpose of the Study:

  • To investigate the association between bronchial mucosal inflammatory markers and lung function decline in asthma.
  • To identify specific inflammatory cell types and mediators linked to progressive loss of lung function over 14 years.

Main Methods:

  • Prospective follow-up study of 19 mild-to-moderate atopic asthma patients over 14 years.
  • Baseline and follow-up assessments included spirometry and bronchoscopy with bronchial biopsies.
  • Biopsies were analyzed for various inflammatory markers including CD4, CD8, CD3, granzyme B, and others.

Main Results:

  • Higher baseline CD8 and CD4 T-cell counts in bronchial mucosa were associated with greater decline in forced expiratory volume in 1 second (FEV1).
  • Elevated CD8, CD3 T-cells, and granzyme B levels at the 14-year follow-up also correlated with accelerated FEV1 decline.
  • Specific inflammatory phenotypes at baseline and follow-up predict long-term lung function deterioration in asthma.

Conclusions:

  • Bronchial CD8 and CD4 T-cell elevations at baseline are linked to long-term lung function decline in asthma.
  • Inflammatory markers including CD8, CD3, and granzyme B at follow-up also predict FEV1 decline.
  • These findings suggest that inflammatory profiles can identify asthma patients at higher risk for progressive lung function loss.